Skip to main content
SpringerLink
Log in

Locoregional Therapies for Hepatocellular Carcinoma

  • Chapter
  • First Online:
Book cover Precision Molecular Pathology of Liver Cancer

Part of the book series: Molecular Pathology Library ((MPLB))

  • 969 Accesses

Abstract

Despite the widespread implementation of surveillance programs for populations with chronic liver disease, more than half of patients with hepatocellular carcinoma (HCC) are diagnosed outside of criteria for curative treatment [1]. Many who receive therapy are subject to new or recurrent disease as a result of an underlying malignant hepatic parenchymal field defect [2]. Management of liver cancer is further complicated by variable hepatic substrate function which, in advanced disease, may pose greater threat to life than HCC [3]. Unlike traditional TNM staging systems, HCC treatment algorithms must factor physiologic reserve, patient performance, and expected disease control rates after transplantation. The Barcelona Clinic Liver Cancer (BCLC) classification is generally adopted in Western nations as the standard protocol to manage patients with HCC as endorsed by the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) [3, 4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Kim WR, Gores GJ, Benson JT, Therneau TM, Melton LJ. Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology. 2005;129(2):486–93.

    Article  PubMed  Google Scholar 

  2. Cucchetti A, Piscaglia F, Caturelli E, Benvegnù L, Vivarelli M, Ercolani G, et al. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol. 2009;16(2):413–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19034578

    Article  PubMed  Google Scholar 

  3. Bruix J, Sherman M. AASLD PRACTICE GUIDELINE Management of hepatocellular carcinoma : an update. Hepatology. 2010;42:1–35. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21374666

    Google Scholar 

  4. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35(3):421–30.

    Article  CAS  PubMed  Google Scholar 

  5. Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford). 2005;7(1):26–34.

    Article  Google Scholar 

  6. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47.

    Article  CAS  PubMed  Google Scholar 

  7. McEvoy SH, McCarthy CJ, Lavelle LP, Moran DE, Cantwell CP, Skehan SJ, et al. Hepatocellular carcinoma: illustrated guide to systematic radiologic diagnosis and staging according to guidelines of the American Association for the Study of Liver Diseases. Radiographics. 2013;33(6):1653–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24108556/nhttp://radiographics.rsna.org/content/33/6/1653.short

    Google Scholar 

  8. Erhardt A, Lörke J, Vogt C, Poremba C, Willers R, Sagir A, et al. [Transient elastography for diagnosing liver cirrhosis]. Dtsch Med Wochenschr. 2006;131(49):2765–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17136655

  9. Shiina S, Tateishi R, Imamura M, Teratani T, Koike Y, Sato S, et al. Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors. Liver Int. 2012;32(9):1434–42. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3466412&tool=pmcentrez&rendertype=abstract

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Bouza C, López-Cuadrado T, Alcázar R, Saz-Parkinson Z, Amate J. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol. 2009;9(1):31. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3224700&tool=pmcentrez&rendertype=abstract

    Article  PubMed  PubMed Central  Google Scholar 

  11. Gervais DA, Goldberg SN, Brown DB, Soulen MC, Millward SF, Rajan DK. Society of Interventional Radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors. J Vasc Interv Radiol. 2009;20(7):S342–7. https://doi.org/10.1016/j.jvir.2009.04.029

    Article  PubMed  Google Scholar 

  12. Dufour JF, Greten TF, Raymond E, Roskams T, De T, Ducreux M, et al. Clinical Practice Guidelines EASL – EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma European Organisation for Research and Treatment of Cancer. J Hepatol. 2012;56(4):908–43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22424438

    Article  Google Scholar 

  13. Brace CL. Radiofrequency and microwave ablation of the liver, lung, kidney, and bone: what are the differences? Curr Probl Diagn Radiol. 2009;38(3):135–43. https://doi.org/10.1067/j.cpradiol.2007.10.001

    Article  PubMed  PubMed Central  Google Scholar 

  14. Weis S, Franke A, Mössner J, Jakobsen JC, Schoppmeyer K. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane database Syst Rev. 2013;12:CD003046. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24357457.

  15. Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;262(1):43–58. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22190656

    Article  PubMed  Google Scholar 

  16. Feng K, Ma K-S. Value of radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Gastroenterol. 2014;20(20):5987–98. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4033438&tool=pmcentrez&rendertype=abstract

    Article  PubMed  PubMed Central  Google Scholar 

  17. Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev. 2007;33(5):437–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17512669

    Article  CAS  PubMed  Google Scholar 

  18. Kumar N, Gaba RC, Knuttinen MG, Omene BO, Martinez BK, Owens CA, et al. Tract seeding following radiofrequency ablation for hepatocellular carcinoma: prevention, detection, and management. Semin Intervent Radiol. 2011;28:187–92.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Brace CL. Microwave tissue ablation: biophysics, technology, and applications. Crit Rev Biomed Eng. 2010;38(1):65–78. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3058696&tool=pmcentrez&rendertype=abstract

    Article  PubMed  PubMed Central  Google Scholar 

  20. Zhang L, Wang N, Shen Q, Cheng W, Qian GJ. Therapeutic efficacy of percutaneous radiofrequency ablation versus microwave ablation for hepatocellular carcinoma. PLoS One. 2013;8(10):1–8.

    CAS  Google Scholar 

  21. Groeschl RT, Pilgrim CHC, Hanna EM, Simo KA, Swan RZ, Sindram D, et al. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg. 2014;259(6):1195–200. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24096760

    Article  PubMed  Google Scholar 

  22. Gage AA. History of cryosurgery. Semin Surg Oncol. 1998;14(2):99–109. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10940055

    Article  CAS  PubMed  Google Scholar 

  23. Yiu WK, Basco MT, Aruny JE, Cheng SWK, Sumpio BE. Cryosurgery: a review. Int J Angiol. 2007;16(1):1–6.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Seifert JK, Stewart GJ, Hewitt PM, Bolton EJ, Junginger T, Morris DL. Interleukin-6 and tumor necrosis factor-alpha levels following hepatic cryotherapy: association with volume and duration of freezing. World J Surg. 1999;23(10):1019–26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10512941

    Article  CAS  PubMed  Google Scholar 

  25. Kariappa SM, Morris DL. Cryotherapy—a mature ablation technique. HPB (Oxford). 2006;8(3):179–81. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2131681&tool=pmcentrez&rendertype=abstract

    Article  Google Scholar 

  26. Awad T, Thorlund K, Gluud C. Cryotherapy for hepatocellular carcinoma. Cochrane Database Syst Rev. 2009;7(4):CD007611.

    Google Scholar 

  27. Rong G, Bai W, Wang C. Cryotherapy for cirrhosis-based hepatocellular carcinoma: a single center experience from 1595 treated cases. Front Med. 2015;9(1):63–71.

    Article  PubMed  Google Scholar 

  28. Granot Y, Rubinsky B. Mass transfer model for drug delivery in tissue cells with reversible electroporation. Int J Heat Mass Transf. 2008;51(23–24):5610–6. https://doi.org/10.1016/j.ijheatmasstransfer.2008.04.041

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Faroja M, Ahmed M, Appelbaum L, Ben-David E, Moussa M, Sosna J, et al. Irreversible electroporation ablation: is all the damage nonthermal? Radiology. 2013;266(2):462–70.

    Article  PubMed  Google Scholar 

  30. Onik G, Mikus P, Rubinsky B. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat. 2007;6:295–300.

    Article  PubMed  Google Scholar 

  31. Scheffer HJ, Nielsen K, De Jong MC, Van Tilborg AA, Vieveen JM, Bouwman A, et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol. 2014;25(7):997–1011. https://doi.org/10.1016/j.jvir.2014.01.028

    Article  PubMed  Google Scholar 

  32. Martin RCG. Irreversible electroporation of locally advanced pancreatic head adenocarcinoma. J Gastrointest Surg. 2013;17(10):1850–6.

    Article  PubMed  Google Scholar 

  33. Cannon R, Ellis S, Hayes D, Narayanan G, Martin RCG. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol. 2013;107(5):544–9.

    Article  PubMed  Google Scholar 

  34. Lencioni R, Izzo F, Vilgrain V, Crocetti L, Ricke J, Bruix J. Irreversible electroporation for the treatment of early-stage hepatocellular carcinoma: a prospective multicenter phase II clinical trial. J Vasc Interv Radiol. 2012;23 (6):853.e3. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed10&AN=70810653\nhttp://sfx.ucl.ac.uk/sfx_local?sid=OVID:embase&id=pmid:&id=doi:10.1016/j.jvir.2012.04.029&issn=1051-0443&isbn=&volume=23&issue=6&spage=853&pages=853.e3&date=2012&ti

    Google Scholar 

  35. Eichler K, Zangos S, Gruber-Rouh T, Vogl TJ, Mack MG. Magnetic resonance-guided laser-induced thermotherapy in patients with oligonodular hepatocellular carcinoma: long-term results over a 15-year period. J Clin Gastroenterol. 2012;46(9):796–801. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22955262

    Article  CAS  PubMed  Google Scholar 

  36. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68(1):13–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17448867

    Article  PubMed  Google Scholar 

  37. Kruskal JB, Hlatky L, Hahnfeldt P, Teramoto K, Stokes KR, Clouse ME. In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol. 1993;4(6):741–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8280994

    Article  CAS  PubMed  Google Scholar 

  38. Lewandowski RJ, Mulcahy MF, Kulik LM, Riaz A, Ryu RK, Baker TB, et al. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology. 2010;255(3):955–65. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2948657&tool=pmcentrez&rendertype=abstract

    Article  PubMed  PubMed Central  Google Scholar 

  39. Nicolini A, Martinetti L, Crespi S, Maggioni M, Sangiovanni A. Transarterial chemoembolization with Epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol. 2010;21(3):327–32. https://doi.org/10.1016/j.jvir.2009.10.038

    Article  PubMed  Google Scholar 

  40. Luo D, Wang Z, Wu J, Jiang C, Wu J. The role of hypoxia inducible factor-1 in hepatocellular carcinoma. Biomed Res Int. 2014;2014:409272. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4101982&tool=pmcentrez&rendertype=abstract

    PubMed  PubMed Central  Google Scholar 

  41. Gurney H. How to calculate the dose of chemotherapy. Br J Cancer. 2002;86:1297–302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Quirk M, Yun K, Saab S. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gatroenterol. 2015;21(12):3462–71.

    Article  CAS  Google Scholar 

  43. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (London, England). 2002;359(9319):1734–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12049862

    Article  Google Scholar 

  44. Lo C-M, Ngan H, Tso W-K, Liu C-L, Lam C-M, Poon RT-P, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11981766

    Article  CAS  PubMed  Google Scholar 

  45. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46(3):474–81. Available from: http://www.sciencedirect.com/science/article/pii/S0168827806006295

    Article  CAS  PubMed  Google Scholar 

  46. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION v study. Cardiovasc Intervent Radiol. 2010;33(1):41–52.

    Article  PubMed  Google Scholar 

  47. Aoki T, Imamura H, Hasegawa K, Matsukura A, Sano K, Sugawara Y, et al. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg. 2004;139(7):766–74.

    Article  PubMed  Google Scholar 

  48. May BJ, Madoff DC. Portal vein embolization: rationale, technique, and current application. Semin Intervent Radiol. 2012;29(212):81–9.

    PubMed  PubMed Central  Google Scholar 

  49. Ribero D, Abdalla E. Tumor progression after preoperative portal vein embolization. Br J Surg. 2007;256(5):812–7; discussion 817–8. Available from: http://onlinelibrary.wiley.com/doi/10.1002/bjs.5836/full

  50. Kataria T, Rawat S, Sinha SN, Negi PS, Garg C, Bhalla NK, et al. Intensity modulated radiotherapy in abdominal malignancies: our experience in reducing the dose to normal structures as compared to the gross tumor. J Cancer Res Ther. 2006;2(4):161–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17998698

    Article  PubMed  Google Scholar 

  51. Cremonesi M, Chiesa C, Strigari L, Ferrari M, Botta F, Guerriero F, et al. Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol. 2014;4:210. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4137387&tool=pmcentrez&rendertype=abstract

    Article  PubMed  PubMed Central  Google Scholar 

  52. Lewandowski RJ, Salem R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin Intervent Radiol. 2006;23(1):64–72.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Padia SA, Kwan SW, Roudsari B, Monsky WL, Coveler A, Harris WP. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol. 2014;25(7):1067–73. Available from: https://doi.org/10.1016/j.jvir.2014.03.030\nhttp://www.ncbi.nlm.nih.gov/pubmed/24837982\nhttp://www.sciencedirect.com/science/article/pii/S105104431400400X

  54. Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60(1):192–201.

    Article  PubMed  Google Scholar 

  55. Thuluvath P. Vascular invasion is the most important predictor of survival in HCC, but how do we find it? J Clin Gastroenterol. 2009;2(43):101–2.

    Article  Google Scholar 

  56. Pracht M, Edeline J, Lenoir L, Latournerie M, Mesbah H, Audrain O, et al. Lobar hepatocellular carcinoma with ipsilateral portal vein tumor thrombosis treated with yttrium-90 glass microsphere radioembolization: preliminary results. Int J Hepatol. 2013;2013:827649. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3586521&tool=pmcentrez&rendertype=abstract

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Lau W-Y, Sangro B, Chen P-J, Cheng S-Q, Chow P, Lee R-C, et al. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology. 2013;84(5):311–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23615394

    Article  CAS  PubMed  Google Scholar 

  58. Siddiqi NH, Devlin PM. Radiation lobectomy-a minimally invasive treatment model for liver cancer: case report. J Vasc Interv Radiol. 2009;20(5):664–9. https://doi.org/10.1016/j.jvir.2009.01.023

    Article  PubMed  Google Scholar 

  59. Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol. 2013;59(5):1029–36. https://doi.org/10.1016/j.jhep.2013.06.015

    Article  PubMed  PubMed Central  Google Scholar 

  60. Hilgard P, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52(5):1741–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21038413

    Article  CAS  PubMed  Google Scholar 

  61. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47(1):71–81.

    Article  PubMed  Google Scholar 

  62. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920–8.

    Article  CAS  PubMed  Google Scholar 

  63. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(2):497–507.e2. https://doi.org/10.1053/j.gastro.2010.10.049

    Article  PubMed  Google Scholar 

  64. Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol. 2013;11(10):1358–65.e1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23644386

    Article  PubMed  Google Scholar 

  65. Seinstra BA, Defreyne L, Lambert B, Lam MGEH, Verkooijen HM, van Erpecum KJ, et al. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Trials. 2012;13:144. Available from: /pmc/articles/PMC3493260/?report=abstract

    Article  PubMed  PubMed Central  Google Scholar 

  66. Yan S, Xu D, Sun B. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci. 2013;58(7):2107–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23361576

    Article  CAS  PubMed  Google Scholar 

  67. Jiang G, Xiaojun X, Sontgao R. Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma. Tumor Biol. 2014;35(4):3405–8.

    Article  CAS  Google Scholar 

  68. Lu Z, Wen F, Guo Q, Liang H, Mao X, Sun H. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol. 2012;25(2):187–94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23134976

    Article  Google Scholar 

  69. Maluccio M, Covey AM, Gandhi R, Gonen M, Getrajdman GI, Brody LA, et al. Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. J Vasc Interv Radiol. 2005;16(7):955–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16002503

    Article  PubMed  Google Scholar 

  70. Erhardt A, Kolligs F, Dollinger M, Schott E, Wege H, Bitzer M, et al. TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. Cancer Chemother Pharmacol. 2014;74(5):947–54. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=25173458

    Article  CAS  PubMed  Google Scholar 

  71. Hickey R, Mulcahy MF, Lewandowski RJ, Gates VL, Vouche M, Habib A, et al. Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. Int J Radiat Oncol Biol Phys. 2014;88(5):1025–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24661655

    Article  PubMed  Google Scholar 

  72. Ricke J, Bulla K, Kolligs F, Peck-Radosavljevic M, Reimer P, Sangro B, et al. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. Liver Int. 2014;35:620–6.

    Article  PubMed  Google Scholar 

  73. Kulik L, Vouche M, Koppe S, Lewandowski RJ, Mulcahy MF, Ganger D, et al. Prospective randomized pilot study of Y90+/−sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol. 2014;61(2):309–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24681342

    Article  CAS  PubMed  Google Scholar 

  74. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20175033

    Article  CAS  PubMed  Google Scholar 

  75. Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol. 2011;54(4):695–704. Available from: http://www.sciencedirect.com/science/article/pii/S0168827810009104

    Article  PubMed  Google Scholar 

  76. Bibault J-E, Dewas S, Vautravers-Dewas C, Hollebecque A, Jarraya H, Lacornerie T, et al. Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity. PLoS One. 2013;8(10):e77472. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3795696&tool=pmcentrez&rendertype=abstract

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Chan ACY, Cheung TT, Fan ST, Chok KSH, Chan SC, Poon RTP, et al. Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. Ann Surg. 2013;257(4):686–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23426335

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, University of Florida College of Medicine, Gainesville, FL, USA

    Beau Toskich M.D.

Authors
  1. Beau Toskich M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Beau Toskich M.D. .

Editor information

Editors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School and New Jersey Medical School, Newark, New Jersey, USA

    Chen Liu

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Toskich, B. (2018). Locoregional Therapies for Hepatocellular Carcinoma. In: Liu, C. (eds) Precision Molecular Pathology of Liver Cancer. Molecular Pathology Library. Springer, Cham. https://doi.org/10.1007/978-3-319-68082-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-68082-8_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-68080-4

  • Online ISBN: 978-3-319-68082-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation